1. Home
  2. APLM vs ZBAI Comparison

APLM vs ZBAI Comparison

Compare APLM & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • APLM
  • ZBAI
  • Stock Information
  • Founded
  • APLM 2016
  • ZBAI 2015
  • Country
  • APLM United States
  • ZBAI United States
  • Employees
  • APLM N/A
  • ZBAI N/A
  • Industry
  • APLM Blank Checks
  • ZBAI Professional Services
  • Sector
  • APLM Finance
  • ZBAI Consumer Discretionary
  • Exchange
  • APLM Nasdaq
  • ZBAI Nasdaq
  • Market Cap
  • APLM 6.1M
  • ZBAI 6.5M
  • IPO Year
  • APLM N/A
  • ZBAI N/A
  • Fundamental
  • Price
  • APLM $5.80
  • ZBAI $6.11
  • Analyst Decision
  • APLM
  • ZBAI
  • Analyst Count
  • APLM 0
  • ZBAI 0
  • Target Price
  • APLM N/A
  • ZBAI N/A
  • AVG Volume (30 Days)
  • APLM 47.7K
  • ZBAI 69.5K
  • Earning Date
  • APLM 08-18-2025
  • ZBAI 06-06-2025
  • Dividend Yield
  • APLM N/A
  • ZBAI N/A
  • EPS Growth
  • APLM N/A
  • ZBAI N/A
  • EPS
  • APLM N/A
  • ZBAI N/A
  • Revenue
  • APLM $198,000.00
  • ZBAI $720,000.00
  • Revenue This Year
  • APLM $415.15
  • ZBAI N/A
  • Revenue Next Year
  • APLM N/A
  • ZBAI N/A
  • P/E Ratio
  • APLM N/A
  • ZBAI N/A
  • Revenue Growth
  • APLM N/A
  • ZBAI 44.00
  • 52 Week Low
  • APLM $4.47
  • ZBAI $4.93
  • 52 Week High
  • APLM $35.98
  • ZBAI $45.00
  • Technical
  • Relative Strength Index (RSI)
  • APLM 47.28
  • ZBAI N/A
  • Support Level
  • APLM $5.41
  • ZBAI N/A
  • Resistance Level
  • APLM $6.38
  • ZBAI N/A
  • Average True Range (ATR)
  • APLM 0.44
  • ZBAI 0.00
  • MACD
  • APLM -0.01
  • ZBAI 0.00
  • Stochastic Oscillator
  • APLM 31.20
  • ZBAI 0.00

About APLM Apollomics Inc.

Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

Share on Social Networks: